Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort [0.03%]
抗瓜尔醛基纤维蛋白原自身抗体(IgG和IgA亚型)有助于早期类风湿关节炎的更好预后分层：来自法国国家ESPOIR队列的数据
Pauline Brevet,Olivia Guérin,Léna Le Goaréguer et al.
Pauline Brevet et al.
Objective: To investigate the prevalence and longitudinal evolution of anti-carbamylated fibrinogen antibodies (ACa-Fib) of IgG and IgA isotypes in early rheumatoid arthritis (RA), and determine whether these antibodies p...
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial [0.03%]
用于活动性银屑病关节炎的Deucravacitinib：来自POETYK PsA-2 随机双盲Ⅲ期试验长达52周的疗效和安全性数据
Philip J Mease,Vinod Chandran,April W Armstrong et al.
Philip J Mease et al.
Objective: To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs ...
Evans Syndrome Predicts Progression to Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus in Children with Persistent Antiphospholipid Antibodies: A Prospective Cohort Study with Up to 29 Years of Follow-up [0.03%]
儿童持续抗磷脂抗体伴有Evans综合征向抗磷脂综合征和/或系统性红斑狼疮进展的前瞻性队列研究：长达29年的随访结果
Vicente Baca,Daniel Hernández-López,Sonia González-Muñiz et al.
Vicente Baca et al.
Objective: To characterize the long-term clinical course of children with hematologic non-criteria manifestations and persistent antiphospholipid antibodies (aPL), and to identify predictors of progression to antiphosphol...
A Multi-Center Integrative Cohort Characterizing the Genetic, Clinical, and Transcriptomic Features of ACP5 Deficiency [0.03%]
多中心整合队列研究揭示ACP5缺乏的遗传、临床和转录组特征
Shiling Zhong,Shuangyue Ma,Yasmine El Chazli et al.
Shiling Zhong et al.
Objectives: Spondyloenchondrodysplasia with immune dysregulation (SPENCDI) is a rare disorder caused by biallelic mutations in ACP5. This study systematically evaluates genetic landscape, clinical features, treatment, and...
BCMA-CD19 CAR T Cells in Systemic Lupus Erythematosus: Humoral Reset or Antigen-Specific Tolerance? [0.03%]
系统性红斑狼疮中的BCMA-CD19 CAR-T细胞：重置体液免疫还是抗原特异性耐受？
Amir Muhammad,Qiongjing Yuan,Ling Yuan et al.
Amir Muhammad et al.
Dermatomyositis in Skin of Color Population - Expanding Clinical Recognition [0.03%]
肤色人群的皮肌炎——扩大临床认识
Urmi Khanna,Andrea Maderal
Urmi Khanna
The Role of Anti-Phosphatidylserine/Prothrombin Antibodies and the Lectin Complement Pathway in Anti-Phospholipid Antibody-Associated Preterm Delivery [0.03%]
抗磷脂抗体相关性早期流产与抗磷脂丝氨酸/凝血酶原抗体及补体讲连途径的作用关系研究
Arianna Da Via,Maria O Borghi,Laura Trespidi et al.
Arianna Da Via et al.
Objective: Antiphospholipid antibodies (aPL) may directly affect placentation and trigger local complement-mediated inflammation/thrombosis. Obstetric complications in the antiphospholipid syndrome (APS) are still frequen...
Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study [0.03%]
儿童和青少年活动性幼年特发性关节炎英夫利西珠单抗药代动力学、疗效和安全性：一项多中心开放标签研究9年+结果
Hermine I Brunner,Lyudmila Grebenkina,Irina Nikishina et al.
Hermine I Brunner et al.
Objective: To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular-course juvenile idiopathic arthritis (pcJIA). ...
Non-melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin-6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study [0.03%]
与白细胞介素-6受体抑制剂相比，jak抑制剂用于类风湿关节炎患者的皮肤癌风险：全国队列研究结果
Zixing Tian,Lianne Kearsley-Fleet,Sizheng Steven Zhao et al.
Zixing Tian et al.
Background: Non-melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin-6 receptor inhi...